V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies - sprookjes - yvandenbroek - TriplyDB

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

http://www.wikidata.org/entity/Q28469283

about

Novel approaches to inhibit HIV entry Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus Reliable genotypic tropism tests for the major HIV-1 subtypes Use of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing.Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120 Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo.Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain How HIV changes its tropism: evolution and adaptation?Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality

P2860

Q27013957-5C964AE5-B96C-482B-8985-07402A1F922B Q27312441-F939CDA8-6755-473F-9C05-AFA2AAFFEF06 Q28475912-FBAB7E27-D799-41D4-A5EA-2AF698B2DECF Q28482091-D4A36166-9E57-4CF4-BA9A-CD354C7FC8CF Q30372085-8C87C6A3-FF96-4A71-87DF-F4AEF51EC959 Q30401569-16D366B5-DE07-4748-8C5C-8795C77D2DBA Q30603475-81A5B21E-2951-410F-A831-149025125EE8 Q30654651-09B88FB7-6D42-431D-8073-33B583DB4482 Q33429049-B2778093-5A7E-48CE-8A05-17B5E32A1980 Q33558676-90F1A933-C3E5-4335-A8A3-BEC84560ECA2 Q33725702-A82A1D33-E0D5-43C8-829C-262C6A5310FD Q33807529-A04F3345-069E-42F9-8AA3-6C0F5A566A32 Q33990552-A9ED8807-1F06-4FCD-A10E-2066613FBFDA Q34055508-AD4021F4-FD7A-4F36-9785-3FF778D99873 Q34299053-8B592384-9D81-42CD-9860-F1DEC2FFC3E1 Q34463861-0372BEAC-B269-4BAC-90B0-2995135580C4 Q34574397-DE0C09D2-9129-4156-A5BA-379554514482 Q34606129-8841AC29-1FCA-4285-A58C-0BBC1779525E Q34610959-B950800A-E9ED-45DE-8F5B-2D1889C87630 Q34611466-EC4D8CB7-C61A-4B0B-A971-81C2ED849189 Q34742873-78DA8F6A-30FE-4415-80AB-EB00D092F2AF Q35102328-BC958A78-BA51-43AE-BB06-E87338F9C3F2 Q35636394-9F4AE021-935B-44A3-AC4F-573FE6371B36 Q35745453-2DFA4C40-9942-4632-8B4D-A8B444481A27 Q36057328-32948352-CB4F-4C7F-A9D1-0B7156640C1D Q36098903-8CA2C03B-DC88-44D5-A36A-7BD4749506A2 Q36424584-A30329D5-A24A-4F56-BF86-0C961E8633CA Q36559608-DE6F1DAB-123F-42A5-B23C-AEFC1DBCDF87 Q36607127-0CC202A0-1F3A-4848-9D51-96F239D0982B Q36742476-F569ED91-729D-4896-89E7-B7014AC9E706 Q36827168-1D6B2096-C2AF-41F4-9F79-42326394B1B1 Q36827946-E4438882-58E2-4BA9-BAEA-463EF139436C Q36949880-362E0C41-D77E-462B-A5F0-5189CD18B63B Q37051645-50C22AC9-F02C-41EF-B72C-F301DA0CED4E Q37145319-EBBD4EE5-5FE1-4BD3-803E-C72812327573 Q37146880-556975E9-B93D-464A-BD93-85EC2C57AC78 Q37191794-EC65D21B-803D-4C1E-BD59-7D53ED9C63A1 Q37192171-69418D8A-5D5B-4E28-8814-FD80806C4DA5 Q37230002-7DFBB430-832C-485D-97AB-C1B59557301A Q37305864-1C79F839-9C99-467E-8369-267F63C31E5F

P2860

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies

http://www.wikidata.org/entity/Q28469283

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@ast

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@en

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@nl

type

label

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@ast

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@en

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@nl

prefLabel

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@ast

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@en

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@nl

P1433

Q28469283-4EE3CAEA-C6FB-45EE-B6CF-220977D765C5

P1476

Q28469283-D8316C3D-82D2-404B-86E6-A3D3BA93FBCF

P2093

Q28469283-2DA18A1D-DC7C-4EC7-AAC1-DC40F18ED2CF

Q28469283-3C2027E6-C66D-4FB2-9899-961D321E8962

Q28469283-779BBB05-564B-4095-9779-10A5FBF8AD47

Q28469283-8D106667-FDD7-44EF-9431-C82CC56A67A7

Q28469283-95343045-4F29-4929-811D-CB733531627D

Q28469283-9DE452E4-EE45-4926-9A84-C5BC563D2419

Q28469283-A103F214-D6AF-4D45-87F6-36E98C78ECDD

Q28469283-C89DBBB6-2355-4DD9-B40B-1CFB63FFDE6E

Q28469283-D70A6239-EFF1-4821-827E-D9A9B8798F2F

Q28469283-DA067640-F0F2-4CA1-8B5A-9AE1F10E15F0

P2860

Q28469283-00FAA942-5B3F-4991-AF5F-3151896D1BDB

Q28469283-02B7865B-45E2-4810-BF49-662D8EF1A63E

Q28469283-032D9CDB-0D67-4BA4-9419-FE15D91F3202

Q28469283-078412DB-7D09-4835-9614-970FE020A222

Q28469283-07C204BE-5D43-45CA-8176-4F9E6ED40E2E

Q28469283-0894804C-29B3-4A50-BD9A-D33D93E5DDE0

Q28469283-095CDB41-B416-49F7-BA06-262263B168AC

Q28469283-0EDCB501-2CB5-42BA-B1F6-E6B694A875DD

Q28469283-13F7822A-0C77-465D-B71A-9B3266E21FD0

Q28469283-147344A0-FFD5-487E-9972-5535C7E909C6

P304

Q28469283-8F26AF3B-DAFE-4581-8EFC-54FB2FD95F72

P31

Q28469283-FE60185A-BF7A-4763-9BE6-D0687CCC6F00

P3181

Q28469283-05C1BCE3-BC2B-4610-AB22-53E2BDF32CA9

P356

Q28469283-D35E8B79-BC52-440A-8602-0A63F2E33A12

P407

Q28469283-A031DB6E-2ABD-43DA-82B7-B247238E3B7E

P433

Q28469283-68264A04-7E92-45BE-A5F1-3F04A2F21C9C

P478

Q28469283-7FF170E0-1738-4567-8E29-C699CDAA277A

P577

Q28469283-C8FBA342-7CA9-478A-8653-6C13DDD6B9A4

P5875

Q28469283-13AEC219-CA12-40D2-9428-1AF18EBB7D8E

P698

Q28469283-F99A4866-F58F-492E-9D27-BCF45BC7D38B

P921

Q28469283-86B526CF-6CE1-43A7-8A90-5566FB5DA9A9

P932

Q28469283-1BE78613-3A89-4638-8F7D-80404CD9F4A3

P3181

P356

JOURNAL.PPAT.0030117

P1433

P1476

V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies

@en

P2093

Andrea P O Jordan

http://www.w3.org/2001/XMLSchema#string

Beth Haggarty

http://www.w3.org/2001/XMLSchema#string

Caroline Agrawal

http://www.w3.org/2001/XMLSchema#string

Eric G Meissner

http://www.w3.org/2001/XMLSchema#string

Fang-Hua Lee

http://www.w3.org/2001/XMLSchema#string

George J Leslie

http://www.w3.org/2001/XMLSchema#string

James A Hoxie

http://www.w3.org/2001/XMLSchema#string

Josephine Romano

http://www.w3.org/2001/XMLSchema#string

Katrina M Nolan

http://www.w3.org/2001/XMLSchema#string

Lishan Su

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans

Structural definition of a conserved neutralization epitope on HIV-1 gp120

HIV and the chemokine system: 10 years later.

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

GP120: target for neutralizing HIV-1 antibodies

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

P304

e117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5019693

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.0030117

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6117324

http://www.w3.org/2001/XMLSchema#string

P698

17722977

http://www.w3.org/2001/XMLSchema#string

P921

P932

1950945

http://www.w3.org/2001/XMLSchema#string